Phase II for BioGard
Thursday, 15 January, 2009
Melbourne company Immuron, formerly known as Anadis, announced its BioGard hyperimmune bovine colostrum product will be studied in a Phase II trial in early stage HIV patients.
BioGard contains anti-lipopolysaccharide antibodies to reduce microbial translocation and immune activation in the gut and other mucosal surfaces. The study will be conducted at Case Western Reserve University hospital in the US.
Last year, the company announced the product would be part of the multi-national Phase IV CORAL study, in conjunction with Merck’s new integrase inhibitor Isentress (raltegravir). That study is set to begin this month.
In addition, a new formulation containing antibodies against HIV envelope antigens will be undertaken by the University of Melbourne’s Associate Professor Damian Purcell, following a research grant awarded by the Department of Health and Ageing.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
